Novartis receives positive CHMP opinion for Ilaris®
"Novartis welcomes the decision by the CHMP in support of…
18 January 2013 | By Novartis
"Novartis welcomes the decision by the CHMP in support of the approval of Ilaris in the EU"
List view / Grid view
"Novartis welcomes the decision by the CHMP in support of…
18 January 2013 | By Novartis
"Novartis welcomes the decision by the CHMP in support of the approval of Ilaris in the EU"
Gilenya® the first once-daily oral therapy...
12 October 2012 | By Novartis
Gilenya® the first once-daily oral therapy...
Seebri® Breezhaler® approved...
1 October 2012 | By Novartis
Seebri® Breezhaler® approved...
Further data from the COPD clinical trial programs...
3 September 2012 | By Novartis
Further data from the COPD clinical trial programs...
CHMP has adopted a positive opinion for Seebri® Breezhaler®...
22 June 2012 | By Novartis
CHMP has adopted a positive opinion for Seebri® Breezhaler®...
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
17 February 2012 | By Novartis
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
Novartis has received regulatory approval in China from the SFDA…
18 January 2012 | By Novartis
Novartis has received regulatory approval in China from the SFDA for Lucentis® (ranibizumab)...
US General Medicines restructuring results in reduction of 1,960 positions...
13 January 2012 | By Novartis
US General Medicines restructuring results in reduction of 1,960 positions...
Once-daily oral MS medicine showed a 48% relative reduction in…
15 December 2011 | By Novartis
Once-daily oral MS medicine showed a 48% relative reduction in annualized relapse rate, meeting primary endpoint in Phase III placebo-controlled study...
Rasitrio®, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide…
28 November 2011 | By Novartis
Rasitrio®, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide in a single pill has received approval...
New pivotal Phase III data announced...
7 November 2011 | By Novartis
New pivotal Phase III data announced...
Novartis will showcase data from 13 abstracts on fingolimod (Gilenya®)...
17 October 2011 | By Novartis
Novartis will showcase data from 13 abstracts on fingolimod (Gilenya®)...
Novartis has received regulatory approval in Japan for once-daily Gilenya…
27 September 2011 | By Novartis
Novartis has received regulatory approval in Japan for once-daily Gilenya (fingolimod)...
Novartis has presented new Phase III data at the ERS…
27 September 2011 | By Novartis
Novartis has presented new Phase III data at the ERS congress...
The CHMP adopted a positive opinion for Rasitrio® for the…
23 September 2011 | By Novartis
The CHMP adopted a positive opinion for Rasitrio® for the treatment of high blood pressure...